CLAPSProject: Conjugated Linoleic Acid on Body Weight and Body Fat Mass for 12 Weeks
Study Details
Study Description
Brief Summary
This study has purpose to assess the effect of conjugated linoleic acid (CLA)-fortified milk powder with nutrition counseling and nutrition module in body weight and body fat mass among overweight and obese adult in Indonesia
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
After being informed of the potential benefits and risks regarding the study, the respondents were asked to sign the consent. The respondents who met the criteria of overweight/ obese without any historical diseases will be randomized into intervention or placebo groups. The intervention will be given for 12 weeks (CLA-fortified milk powder 3.4 gram, once-daily consumption). Both the intervention and placebo groups will also receive nutrition counseling and nutrition module.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: CLA-fortified milk powder Respondents will receive CLA-fortified milk powder containing 3.4 gram for one a day for 12 weeks. They will also receive individualized nutrition counseling and nutrition module at weeks 0, 4, and 8. |
Dietary Supplement: CLA-fortified milk powder
3.4 gram of CLA-fortified milk powder one a day for 12 weeks
Other: Nutrition Counseling
Individualized nutrition counseling using nutrition module at week 0, 4, and 8 for 30-45 minutes each session
|
| Other: Placebo Respondents will receive a placebo milk powder for one a day for 12 weeks. They will also receive individualized nutrition counseling and nutrition module at weeks 0, 4, and 8. |
Other: Placebo
Placebo milk powder one a day for 12 weeks
Other: Nutrition Counseling
Individualized nutrition counseling using nutrition module at week 0, 4, and 8 for 30-45 minutes each session
|
Outcome Measures
Primary Outcome Measures
- Change of body weight [Baseline (after signing the consent) week-0, week-4, week-8, and week-12 (endline)]
to investigate the change of body weight before, during and after intervention. Using Seca® type 876 is calibrated scale to the nearest 0.1 kilogram. The lower body weight indicates better outcome
- Change of body fat mass [Baseline (after signing the consent) week-0 and week-12 (endline)]
to investigate the change of body fat mass before and after intervention. Using Dual-energy X-ray absorptiometry (DXA GE Lunar® Prodigy 64179). The lower body fat mass indicates better outcome
- Change of body fat mass [Baseline (after signing the consent) week-0, week-4, week-8, and week-12 (endline)]
to investigate the change of body fat mass before, during, and after intervention. Using Bod Pod (Cosmed®). The lower body fat mass indicates better outcome
Secondary Outcome Measures
- Change of Waist hip ratio [Baseline (after signing the consent) week-0, week-4, week-8, and week-12 (endline)]
to investigate the change of waist hip ratio before, during, and after intervention. Waist hip ratio is obtained by dividing the waist circumference and hip circumference. Tape measurement (Seca® type 201) is calibrated scale to nearest 0.1 centimeter. The lower body fat mass indicates better outcome
- Change of Low Density Lipoprotein (LDL) [Baseline (after signing the consent) week-0 and week-12 (endline)]
to investigate the change of low density lipoprotein (LDL) in miligram per deciliter before and after intervention. The lower change of LDL indicates the better outcome. Enzymatic method
- Change of High Density Lipoprotein (HDL) [Baseline (after signing the consent) week-0 and week-12 (endline)]
to investigate the change of high density lipoprotein (HDL) in miligram per deciliter before and after intervention. The higher change of HDL indicates the better outcome. Enzymatic method
- Change of Total of Cholesterol [Baseline (after signing the consent) week-0 and week-12 (endline)]
to investigate the change of total of cholesterol in miligram per deciliter before and after intervention. The lower change of total of cholesterol indicates the better outcome. Enzymatic method
- Change of Triglyceride [Baseline (after signing the consent) week-0 and week-12 (endline)]
to investigate the change of triglyceride in miligram per deciliter before and after intervention. The lower change of triglyceride indicates the better outcome. Enzymatic method
- Dietary intake (semi quantitative food frequency questionnaire) [Baseline (after signing the consent) week-0, week-8 and week-12 (endline)]
to investigate the dietary intake before, during, and after intervention using semi quantitative food frequency questionnaire. The higher number of dietary intake indicates the better outcome
- Dietary intake (24-hours recall) [Baseline (after signing the consent) week-0, week-8 and week-12 (endline)]
to investigate the dietary intake before, during, and after intervention using 24-hours recall. The higher dietary intake indicates the better outcome
- Change of knowledge [Baseline (after signing the consent) week-0 and week-12 (endline)]
to investigate the score of knowledge before and after the intervention. Using validated questionnaire of knowledge. Minimum score is 0 and maximum score is 100.The higher score of knowledge after intervention indicates the better outcome.
- Change of attitude [Baseline (after signing the consent) week-0 and week-12 (endline)]
to investigate the score of attitude before and after the intervention. Using validated questionnaire of attitude. Minimum score is 0, maximum score is 100. The higher score of attitude after intervention indicates the better outcome.
- Physical activity level [Baseline (after signing the consent) week-0, week-4, week-8, and week-12 (endline)]
to investigate the physical activity level before, during and after intervention. Using International Physical Activity Questionnaire. The category of physical activity level are low (<600 metabolic equivalents), moderate (>=600 - 3000 metabolic equivalents) and high (>=3000 metabolic equivalents).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Body mass index (BMI) 23 - 24.9 kg/m2 for overweight and ≥ 25 kg/m2 for obese
-
Fat mass percentage (FM%) of ≥ 20% for men and ≥ 30% for women
-
Agree to follow the study
Exclusion Criteria:
-
Lactose intolerance
-
Undergoing treatment (e.g., antibiotics and/or anti-inflammatory or immunosuppressant drugs and weight loss)
-
Any physical condition that might be contraindicated to dietary restrictions
-
Any non-communicable disease (e.g., Diabetes Mellitus, Chronic Kidney Disease, Cancer, Hypertension)
-
Pregnant
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Faculty of Medicine Universitas Indonesia | Jakarta Pusat | Jakarta | Indonesia | 10430 |
Sponsors and Collaborators
- Indonesia University
- BASF
Investigators
- Principal Investigator: Fiastuti Witjaksono, Doctoral, Department of Nutrition, Faculty of Medicine of Universitas Indonesia
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 19-10-1189